ECSP12011631A - Composición de insulina de acción prolongada - Google Patents

Composición de insulina de acción prolongada

Info

Publication number
ECSP12011631A
ECSP12011631A EC2012011631A ECSP12011631A ECSP12011631A EC SP12011631 A ECSP12011631 A EC SP12011631A EC 2012011631 A EC2012011631 A EC 2012011631A EC SP12011631 A ECSP12011631 A EC SP12011631A EC SP12011631 A ECSP12011631 A EC SP12011631A
Authority
EC
Ecuador
Prior art keywords
insulin compound
pharmaceutical composition
insulin composition
present
prolonged insulin
Prior art date
Application number
EC2012011631A
Other languages
English (en)
Inventor
Kennett Sprogoe
Felix Cleemann
Ulrich Hersel
Silvia Kaden-Vagt
Torben Lessmann
Harald Rau
Thomas Wegge
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of ECSP12011631A publication Critical patent/ECSP12011631A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende un compuesto de insulina en una concentración suficiente para mantener un nivel terapéuticamente eficaz del compuesto de insulina en el plasma sanguíneo durante por lo menos 3 días, caracterizada porque tiene un perfil de farmacocinética in vivo que prácticamente no exhibe absorción rápida del compuesto de insulina. La presente invención se refiere además al uso de un compuesto de insulina para preparar dicha composición farmacéutica, como también a un kit de partes que comprende dicha composición farmacéutica.
EC2012011631A 2009-07-31 2012-01-30 Composición de insulina de acción prolongada ECSP12011631A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09167017 2009-07-31
EP09179337 2009-12-15
EP09179827 2009-12-18

Publications (1)

Publication Number Publication Date
ECSP12011631A true ECSP12011631A (es) 2012-02-29

Family

ID=43033453

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2012011631A ECSP12011631A (es) 2009-07-31 2012-01-30 Composición de insulina de acción prolongada

Country Status (29)

Country Link
US (1) US9265723B2 (es)
EP (1) EP2459171B1 (es)
JP (1) JP5732053B2 (es)
KR (1) KR101759499B1 (es)
CN (1) CN102625695B (es)
AU (1) AU2010277560B2 (es)
BR (1) BR112012001988A2 (es)
CA (1) CA2769540C (es)
CL (1) CL2012000469A1 (es)
CO (1) CO6491085A2 (es)
CR (1) CR20120019A (es)
DK (1) DK2459171T3 (es)
EC (1) ECSP12011631A (es)
ES (1) ES2636741T3 (es)
GT (1) GT201200020A (es)
IL (1) IL217613A (es)
MA (1) MA33466B1 (es)
MX (1) MX2012001141A (es)
NI (1) NI201200013A (es)
NZ (1) NZ597964A (es)
PE (1) PE20121170A1 (es)
PL (1) PL2459171T3 (es)
PT (1) PT2459171T (es)
RU (1) RU2556340C2 (es)
SG (1) SG178195A1 (es)
TN (1) TN2012000010A1 (es)
UA (1) UA108475C2 (es)
WO (1) WO2011012719A1 (es)
ZA (1) ZA201200224B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2786794C (en) * 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
DK2459171T3 (en) 2009-07-31 2017-09-25 Sanofi Aventis Deutschland Long-acting insulin composition
KR20120089843A (ko) 2009-07-31 2012-08-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 링커 접합체를 포함한 프로드럭
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
AU2012216648C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2014006391A (es) * 2011-11-28 2014-09-22 Phasebio Pharmaceuticals Inc Agentes terapéuticos que comprenden secuencias de aminoácidos de insulina.
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US20150231334A1 (en) * 2013-12-18 2015-08-20 Windgap Medical, Inc. Drug mixing and delivery system and method
US12239822B2 (en) 2013-03-15 2025-03-04 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
EP3517122A1 (en) 2013-04-03 2019-07-31 Sanofi Treatment of diabetes mellitus by long-acting formulations of insulins
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
JP7173953B2 (ja) * 2014-01-09 2022-11-16 サノフイ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
JP2020114861A (ja) * 2014-01-09 2020-07-30 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
CA2932873A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
KR20160104726A (ko) * 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN103830189A (zh) * 2014-03-04 2014-06-04 山东新时代药业有限公司 一种重组甘精胰岛素制剂及其制备方法
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
CN107205938A (zh) 2014-12-18 2017-09-26 温德加普医疗股份有限公司 用于溶解或增溶治疗剂的方法和组合物
CN105796508A (zh) * 2014-12-30 2016-07-27 江苏万邦生化医药股份有限公司 甘精胰岛素缓释微球、甘精胰岛素微球注射剂及其制备方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
SI3423103T1 (sl) 2016-03-01 2024-12-31 Ascendis Pharma Bone Diseases A/S Predzdravila PTH
EP3515408A1 (en) 2016-09-23 2019-07-31 Delpor, Inc. Stable compositions for incretin mimetic compounds
JP7039574B2 (ja) 2016-09-29 2022-03-22 アセンディス ファーマ ボーン ディジージズ エー／エス 放出制御ｐｔｈ化合物の漸増用量設定
KR102611820B1 (ko) 2016-09-29 2023-12-07 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
HUE063235T2 (hu) * 2016-09-29 2024-01-28 Ascendis Pharma Bone Diseases As Adagolási rendszer szabályozott leadású PTH vegyülethez
US10869851B1 (en) * 2017-03-13 2020-12-22 The United States Government As Represented By The Secretary Of The Army Targeting NUR77 for mitigating perinatal neuroinflammation
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
US20220040099A1 (en) * 2017-12-06 2022-02-10 Adocia Injectable solution at ph 7 comprising at least a basal insulin which pi is comprised between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
AU2020221491B2 (en) 2019-02-11 2025-02-27 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
US12435116B2 (en) 2019-10-16 2025-10-07 Clarence Hurt Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
KR102945259B1 (ko) * 2021-09-30 2026-03-27 주식회사 엘지화학 마이크로 캐리어, 세포 복합체 및 이를 포함하는 의료용 조성물, 미용 조성물, 의료 용품 및 미용 용품
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5634943A (en) 1990-07-12 1997-06-03 University Of Miami Injectable polyethylene oxide gel implant and method for production
DE69329594T2 (de) 1992-02-28 2001-05-31 Board Of Regents, The University Of Texas System Photopolymerinierbare, biologisch abbaubare hydrogele als gewebekontaktmaterialien und trägerstoffe für kontrollierte freisetzung
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE19626762A1 (de) 1996-07-03 1998-01-08 Basf Ag Enzymatisch spaltbare Linker für Festphasensynthesen
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
CA2309356C (en) 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
NZ504258A (en) 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
ES2211033T3 (es) 1998-01-07 2004-07-01 Debio Recherche Pharmaceutique S.A. Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos.
WO1999040788A1 (en) 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
EP1374908A3 (en) 1998-10-09 2004-03-24 The Regents Of The University Of Michigan Polymer-drug conjugates comprising hydrazide linkers
EP1137373A4 (en) 1998-12-04 2004-05-19 Chandrashekhar P Pathak BIOCOMPATIBLE, CROSSLINKED POLYMERS
EP2311895B1 (en) 1999-02-01 2017-04-12 Eidgenössische Technische Hochschule Zürich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
AU765753B2 (en) 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
AU1249001A (en) 1999-06-11 2001-01-31 Nektar Therapeutics Al, Corporation Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers
US6372813B1 (en) 1999-06-25 2002-04-16 Motorola Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP1255823A4 (en) 2000-01-28 2007-10-31 Azopax Therapeutics Llc PROTEIN POLYMERS WITH SLOW RELEASE
US6884778B2 (en) 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
JP4841066B2 (ja) 2000-09-01 2011-12-21 ライスユニバーシティ 酸化窒素生成ヒドロゲル物質
US6537569B2 (en) 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
CA2444880C (en) 2001-04-23 2009-11-24 Wisconsin Alumni Research Foundation Bifunctional-modified hydrogels
KR20030097876A (ko) * 2001-05-21 2003-12-31 넥타르 테라퓨틱스 화학적으로 개질된 인슐린의 폐 투여
EP1306127B2 (en) 2001-10-26 2011-09-07 OctoPlus PolyActive Sciences B.V. Method for the preparation of purified microparticles
US6960298B2 (en) 2001-12-10 2005-11-01 Nanogen, Inc. Mesoporous permeation layers for use on active electronic matrix devices
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
WO2003084926A2 (en) 2002-04-04 2003-10-16 Enzon, Inc. Polymeric acyl derivatives of indoles
DE10221457A1 (de) 2002-05-15 2003-11-27 Behr Gmbh & Co Wärmeübertrager und Verfahren zu seiner Herstellung
JP2005535604A (ja) 2002-06-03 2005-11-24 アルニス バイオサイエンシーズ， インコーポレイテッド 治療剤を含むポリマーナノ物品
JP2005528913A (ja) 2002-06-10 2005-09-29 メルク　エンド　カムパニー　インコーポレーテッド 新規動原体関連モータータンパク質をコードする単離核酸分子及びその使用
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
CA2786794C (en) * 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
EP1586334A1 (en) 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
JPWO2006038462A1 (ja) 2004-10-01 2008-05-15 国立大学法人九州大学 新規ステロイド産生細胞
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
US20060115865A1 (en) 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US7407117B2 (en) 2004-10-28 2008-08-05 Meadwestvaco Calmar, Inc. Liquid sprayer assembly
JP2006163996A (ja) 2004-12-09 2006-06-22 Evolium Sas 行動履歴に基づくプッシュ型の情報提供システム
US20090233841A1 (en) 2005-01-05 2009-09-17 Regents Of The University Of Minnesota Analgesic conjugates
KR100665672B1 (ko) 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2007204815A1 (en) 2006-01-12 2007-07-19 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
EP1840152B1 (en) 2006-03-31 2009-07-08 Sony Deutschland Gmbh A method of forming a crosslinked polymer gel
CA2653200A1 (en) 2006-05-25 2007-12-06 The General Hospital Corporation Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
WO2008034122A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
GB0619175D0 (en) 2006-09-29 2006-11-08 Univ Nottingham Polymer
JP5539725B2 (ja) 2006-11-27 2014-07-02 アクタマックス サージカル マテリアルズ リミテッド ライアビリティ カンパニー 分岐末端反応物及びそれから製造されるポリマーヒドロゲル組織接着剤
WO2008097581A1 (en) 2007-02-06 2008-08-14 Incept, Llc Polymerization with precipitation of proteins for elution in physiological solution
US20080220047A1 (en) 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
WO2008116913A2 (en) 2007-03-28 2008-10-02 Novo Nordisk A/S Peptide compounds with transient biodegradable pegylation
WO2008125655A1 (en) 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
JP2010525033A (ja) * 2007-04-30 2010-07-22 ノボ・ノルデイスク・エー／エス 高濃縮のインスリン溶液及び組成物
WO2008148839A2 (en) 2007-06-08 2008-12-11 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
EP2170945A1 (en) * 2007-07-16 2010-04-07 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
LT2237799T (lt) 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
EP2247645B1 (en) 2008-02-13 2017-12-06 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
US20110118189A1 (en) 2008-04-28 2011-05-19 Farr Stephen J Novel formulations for treatment of migraine
CA3004716C (en) 2008-04-29 2022-04-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
CN102413843A (zh) 2009-03-05 2012-04-11 阿森迪斯药物股份有限公司 干扰素α载体前药
DK2459171T3 (en) 2009-07-31 2017-09-25 Sanofi Aventis Deutschland Long-acting insulin composition
LT2459220T (lt) 2009-07-31 2020-12-28 Ascendis Pharma A/S Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu
KR20120089843A (ko) 2009-07-31 2012-08-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 링커 접합체를 포함한 프로드럭
AU2010311421B2 (en) 2009-10-29 2014-11-20 Ascendis Pharma A/S Sterilization of biodegradable hydrogels
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate

Also Published As

Publication number Publication date
CN102625695A (zh) 2012-08-01
US20120183616A1 (en) 2012-07-19
SG178195A1 (en) 2012-03-29
PL2459171T3 (pl) 2017-11-30
MA33466B1 (fr) 2012-07-03
DK2459171T3 (en) 2017-09-25
RU2012107487A (ru) 2013-09-10
BR112012001988A2 (pt) 2017-05-09
RU2556340C2 (ru) 2015-07-10
WO2011012719A1 (en) 2011-02-03
AU2010277560A1 (en) 2012-02-23
KR101759499B1 (ko) 2017-07-19
MX2012001141A (es) 2012-03-29
IL217613A (en) 2016-08-31
CA2769540A1 (en) 2011-02-03
CN102625695B (zh) 2015-05-27
UA108475C2 (uk) 2015-05-12
ES2636741T3 (es) 2017-10-09
GT201200020A (es) 2014-09-10
KR20120089261A (ko) 2012-08-09
NZ597964A (en) 2014-04-30
US9265723B2 (en) 2016-02-23
CR20120019A (es) 2012-03-02
TN2012000010A1 (en) 2013-09-19
PT2459171T (pt) 2017-08-16
ZA201200224B (en) 2012-09-26
EP2459171B1 (en) 2017-06-21
JP5732053B2 (ja) 2015-06-10
NI201200013A (es) 2012-05-29
CL2012000469A1 (es) 2012-10-19
CA2769540C (en) 2017-08-15
CO6491085A2 (es) 2012-07-31
JP2013500952A (ja) 2013-01-10
AU2010277560B2 (en) 2014-12-11
PE20121170A1 (es) 2012-09-10
EP2459171A1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
CO6491085A2 (es) Composicion de insulina de accion prolongada
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
PA8841901A1 (es) Compuestos orgánicos
PA8740901A1 (es) Compuestos organicos
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
PA8777101A1 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
MX357820B (es) Composiciones para uso en la manufactura de medicamentos para tratamiento de esclerosis multiple progresiva.
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
MX2012005030A (es) Nuevo uso antitumoral de cabazitaxel.
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
UY32731A (es) Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
ECSP11010816A (es) Nuevos Compuestos
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
EA201491300A1 (ru) Композиция для назального применения с улучшенной стабильностью
CO6290768A2 (es) Tiazolil-dihidro-indazoles
CO6460762A2 (es) 5-alquinil-piridinas
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
ECSP10010642A (es) Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes